Key result
TOP-EVs efficiently deliver target proteins including CRISPR/Cas9 intracellularly in vitro and into liver in vivo.
Why the study?
Effective methods for endogenous loading and unloading of target proteins inside extracellular vesicles are limited, hampering their application as therapeutic delivery vehicles.
TOP-EVs represent a versatile platform for efficient intracellular protein delivery in vitro and in vivo, potentially advancing the development of protein-based therapeutics.
Answers are grounded in this paper and cite their sources.
May advance protein therapeutics for liver disease; leaves open clinical translation pending human studies.
Extracellular vesicles (EVs) have emerged as biocompatible drug delivery vehicles due to their native ability to deliver bioactive cargo to recipient cells. However, the application of EVs as a therapeutic delivery vehicle is hampered by effective methods for endogenously loading target proteins inside EVs and unloading proteins after delivery to recipient cells. Most EV-based engineered loading methods have a limited delivery efficiency owing to their inefficient endosomal escape or cargo release from the intraluminal attachment from the EV membrane. Here, we describe the 'Technology Of Protein delivery through Extracellular Vesicles' (TOP-EVs) as a tool for efficient intracellular delivery of target proteins mediated via EVs. The vesicular stomatitis virus glycoprotein and the rapamycin-heterodimerization of the FKBP12/T82L mutant FRB proteins were both important for the effective protein delivery through TOP-EVs. We showed that TOP-EVs could efficiently deliver Cre recombinase and CRISPR/Cas9 ribonucleoprotein complex in vitro. Moreover, our results demonstrated that the capacity of TOP-EVs to deliver intracellular proteins in recipient cells was not an artifact of plasmid contamination or direct plasmid loading into EVs. Finally, we showed that TOP-EVs could successfully mediate intracellular protein delivery in the liver in vivo. Taken together, TOP-EVs are a versatile platform for efficient intracellular protein delivery in vitro and in vivo, which can be applied to advance the development of protein-based therapeutics.
No takes yet. Share an insight, caveat, or question.
Ilahibaks et al. (2023) studied this question. TOP-EVs (Technology of Protein delivery through Extracellular Vesicles) was evaluated on Intracellular protein delivery. TOP-EVs successfully mediated efficient intracellular delivery of target proteins, including Cre recombinase and CRISPR/Cas9, in vitro and in the liver in vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: